Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC  by Vastagh, E et al.
Efficacy and safety of inhaled budesonide delivered
once or twice daily via HFA-134a in mild to
moderate persistent asthma in adult patients.
Comparison with budesonide CFC
E. Vastagha, P. Kunab, P. Calistruc, M.A. Bogdand, Efficacy on behalf of the
budesonide HFA MDI study group1
aSote T "udogyogyszati Klinica, Budapest, Hungary
bKlinica Pulmonologii i Alergologii, Lodz, Poland
cSpitalul Clinic Victor Babes, Bucharest, Romania
dInstitutul National de Pneumologie Marius Nasta, Bucharest, Romania
Summary This study was undertaken to investigate whether budesonide 400 mg
twice daily (Chiesi Farmaceutici S.p.A.) given with the HFA-134a propellant is
equivalent in efficacy and safety to the same dose regimen delivered with the
marketed CFC product in adult asthmatics with mild to moderate persistent asthma;
the effects of budesonide HFA 800 mg once daily were also studied. After a 2-week
run-in, a total number of 98, 103 and 97 patients were assigned to the 12-week
treatment with budesonide given with HFA or CFC twice daily (morning and evening),
or HFA once daily (morning), respectively. The main outcome variable morning PEFR,
as well as evening PEFR and clinical symptoms (day-time and night-time asthma
attacks, number of asthma-induced night-time awakenings and overall symptoms’
scores) were measured daily by patients. Other standard pulmonary function testing
were measured at clinic visits. A blood sample for morning serum dosing (8.00–10.00
AM) was taken at baseline and at endpoint. Adverse events and vital signs were also
recorded.
Significant improvements at endpoint in morning and evening PEFR, as well as in
clinic PEFR and MEF50, were observed in both the twice daily groups only. An exact
proof of equivalence between HFA and CFC given twice daily was demonstrated for
the primary parameters, morning PEFR (equivalence pre-defined limits were
740.27 l/min, difference between means¼ 4.0 l/min and 95% CI 6.9–14.9) and
secondary parameters as evening PEFR: (limits 740.19 l/min, difference between
means¼ 2.1 l/min and 95% Confidence interval (CI) 9.4–13.5) and FEV1 (limits
70.27 l, difference between means¼ 0.0 l and 95% CI 0.11–0.10). Less evident (but
within limits) proofs of equivalence were shown in the comparisons with the once
daily group. No substantial differences between the three groups were observed for
the other efficacy variables, including symptoms and use of rescue salbutamol,
which significantly improved over the run-in values in all groups.
Minimal and non-significant decreases over pre-treatment values were observed in
the three groups for morning serum cortisol levels: the analysis of individual data has
shown a better outcome in the HFA twice daily regimen, compared with the other two
groups. Again, a similar amount of patients in both the twice daily groups reported
drug-related adverse events, which were more frequent in the once daily HFA group.
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Therefore, the results of this study have shown that inhaled budesonide given with
new HFA-134a propellant can replace microgram-equivalent doses of the corre-
sponding marketed CFC product when given twice daily. An overall maintainment
and an unchanged risk-benefit ratio has emerged for budesonide HFA given once
daily, which was however slightly inferior compared with the standard twice daily
regimens.
& 2003 Published by Elsevier Ltd.
Introduction
The pressurised metered dose inhaler (pMDI) is still
the device of choice for asthma inhalation therapy1
and is an essential therapeutic option for the
estimated more than 300 million people worldwide
who suffer from asthma and the many millions
more affected by a variety of other respiratory
diseases.
Chlorofluorocarbons (CFCs) are still currently
available in Europe and elsewhere for the manu-
facture of MDIs in their essential use exemption.
However, beside the evidence that CFCs (such as
the freons) contained as propellants in MDIs have a
proven damaging effect on the atmospheric ozone
layer,2 an international conference held in Montreal
in 19873 led to a commitment by participating
countries to cease production of these compounds,
and the European Community has set a target date
of 2003 for a no further use of CFC-containing
aerosols.4
In order to provide prescribers, in compliance
with the European guidelines, a variety of pMDIs-
delivered products, mainly bronchodilators and
inhaled glucocorticosteroiods, containing hydro-
fluoroalkane (HFA)-134a as an alternative CFC-free
propellant has been developed. Different ap-
proaches have been used in the development of
non-CFC formulated glucocorticosteroids: the tran-
sition from the fluticasone propionate CFC to HFA-
134a has been possible at a microgram equivalent
dose, as shown in a variety of clinical trials,5–7
while the increased deposition of beclometasone
dipropionate in the lungs has permitted an halved
dosage of the current HFA-marketed product
(QVARs, 3M Healthcare), relative to the CFC
formulation.8
Budesonide is an established and widely used
topically active synthetic glucocorticosteroid. Its
systemic absorption is generally low, and may vary
from 10% to 30% depending on the device and user
technique. The bioavailability of orally adminis-
tered budesonide is about 10% due to extensive
pre-systemic metabolism.9 These favorable proper-
ties have evidenced the need of a safe replacement
of freon-delivered budesonide as a part of CFCs
phasing out: the main objective of the develop-
ment program for the HFA-134a-delivered budeso-
nide used in this study was to produce solution
formulations of the active drug that are equivalent
in terms of efficacy, safety and dose per actuation
to the currently marketed budesonide CFC-contain-
ing products. This objective has been implemented
by applying Chiesi’s proprietary technology (Mod-
ulites), which includes glycerol as a low volatile
co-solvent, in order to obtain a particle size
distribution which mimics that of the CFC -product
to be replaced.
The objective of the present study was to
compare the efficacy and safety of budesonide
800 mg/day propelled with either the HFA-134a or
the marketed CFC in adult patients with mild to
moderate persistent asthma. In view of the
evidence supporting a once daily administration
of inhaled budesonide,10 a third arm with the HFA-
delivered formulation has been included in this
study.
Patients and methods
Patients
This study was carried out in 21 centres across four
European countries (France, Hungary, Poland and
Rumania). Patients aged between 18 and 70 years,
with mild to moderate persistent asthma reversible
to beta2-agonists and with a FEV1 between 60% and
90% of predicted normal were eligible to take part
in the study. Patients satisfying any of the following
criteria were excluded from the participation in the
study: evidence of asthma exacerbation or upper
respiratory tract infection in the previous 8 weeks;
medical history of clinically significant diseases;
intake of oral steroids in the previous 8 weeks;
intake of inhaled corticosteroids at a dose exceed-
ing a corresponding dose of 800 mg/day inhaled
budesonide; inability to abstain from the non-
permitted concomitant medications; pregnancy or
risk of pregnancy, heavy smoking habits (defined as
Z20 cigarettes/day over a 20-year period); hyper-
sensitivity to inhaled corticosteroids. In addition,
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patients were admitted to the treatment phase
provided that their FEV1 did not change (715% vs.
screening) at the end of the 2-week run-in period.
Intake of inhaled rescue salbutamol was per-
mitted at any time (at minimum 6h from pulmon-
ary function testing). Long acting beta2-agonists (at
minimum 12 h from pulmonary function testing),
inhaled or oral sodium cromoglycate or nedocromil
sodium, theophyllines and leukotriene antagonists,
if taken at study entry, were permitted at a
constant dose throughout the study period. Inhaled
corticosteroids could continue at constant daily
dose during the run-in period, whereas antic-
holinergics, oral corticosteroids, and antihista-
mines were not permitted at any time.
Study design, treatment and outcome
measures
This was a 12-week, double blind, double dummy
(the group treated with budesonide HFA given in a
once daily dose was an open control group),
randomised, multinational, multicentre, parallel-
group design study.
After a 2-week run-in period, eligible patients
were randomised to one of the following three
treatment arms: budesonide HFA, or budesonide
CFC (Pulmicorts, AstraZeneca), both given at a
dose of 400 mg twice daily (08.00 AM and 08.00 PM),
or budesonide HFA given at a dose of 800 mg once
daily (08.00 AM). To keep blinding, patients
assigned to the 2 twice daily regimens also received
the alternative placebo.
At each visit, done at study entry, baseline (end
of run-in), and after 2, 4, 8 and 12 weeks of
treatment, the following pulmonary function (PF)
tests were measured according with standard
guidelines:11 forced expiratory volume in 1 s
(FEV1, l), forced vital capacity (FVC, l), peak
expiratory flow rate (PEFR, l/min) and mid ex-
piratory flow at 50% vital capacity (MEF50, l/s).
Three consecutive tests were performed and the
best (that with highest FEV1 reading) was recorded.
Patients also used a portable peak flow meter (Mini-
Wrights, Markos, Italy) to measure their peak flow
(l/min) twice daily (at 08.00 AM and at 08.00 PM);
the best of three readings was used for data
analysis, together with the calculation of daily
peak flow variability using the following formula:12
[PEFR eveningPEFR morning/1/2 (PEFR evening
þ PEFR morning)] 100.
Patients recorded daily the number of puffs of
inhaled salbutamol taken on demand, as well as a
daily symptoms’ score, which was obtained by a 4-
point rating-scale measurement of dyspnoea, ta-
chypnoea, wheezing and cough (0¼ none; 1¼mild;
2¼moderate; 3¼ severe). The frequencies of
salbutamol-free days and symptoms-free days were
also calculated.
A blood sample was taken at baseline and at
week 12, between 08.00 and 10.00 AM, to measure
serum cortisol levels. Assessment was done using
direct radio-immunologic assay (RIA), and was
centralised at MDS Pharma Services Central Lab
(Baillet en France, France), the provided range of
normal value was 250–700 nmol/l.
Adverse events were questioned at each visit and
described in terms of date of onset, date of end,
severity, outcome and correlation with the study
treatment. Vital signs (pulse rate and blood
pressure) were also measured at each clinic visit.
Patients had to record daily on a diary card the
number of administered puffs; a limit for a
satisfactory compliance was set at 75% of scheduled
drug.
Ethics
The study protocol was submitted to and approved
by the Independent Ethics Committees of each
participating centre prior to any study-related
procedure was started. In addition, all patients
were fully informed in writing of the objectives and
implications of the trial and their written informed
consent was obtained before they were enrolled.
Statistics
Once defined the final (weeks 11–12) mean value of
morning PEFR as the primary outcome variable, the
sample size calculation was aimed to satisfy a
criteria of equivalent efficacy between both twice
daily groups.13 The limit for equivalence was set at
a 10% of the mean morning PEFR value (460 l/min)
observed in a sample, drawn from a similar
population, treated with the CFC propellant. Being
a clinical equivalence trial, the test was based on
the calculation of the bilateral confidence interval
(1-2a) of the two means difference. Type I error
was fixed at a¼ 0.025 and type II error was set at
0.2 in order to ensure a 80% power to verify the
hypothesis of equivalence. With an expected
difference between the two formulations equal to
zero and the common standard deviation equal to
90 l/min, each group had to contain 82 patients
(246 in total).
Morning PEFR values were analysed within treat-
ment by calculating, after 4 weeks of treatment
and at the end of study periods, the 95% confidence
interval (CI) for the mean change from baseline; a
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minimum of 10 measurements was required in each
2-week period.
Two by two comparisons between treatment
groups were made using an analysis of covariance
(ANCOVA) model for morning PEFR values recorded
on the last 2-week period. The ANCOVA model
included terms for investigator and treatment
effects and baseline value as a covariate. A
preliminary test for the centre-by treatment inter-
action was performed at 0.10 significance level.
The equivalence between the three test treat-
ments was evaluated by calculating the bilateral
95% CIs for the difference between the least-
squares means (LSMs), from ANCOVA, in the two-by-
two comparisons. The two twice daily test treat-
ments were defined as equivalent if the confidence
limits for the difference fall within the710% of the
LSM of the budesonide group using the CFC
propellant, which was also used as reference drug
in the comparison with the once daily group. When
comparing the two HFA groups, the once daily
regimen was used as reference drug.
Other than morning PEFR, evening PEFR and FEV1
were also tested for equivalence whereas the other
PF tests, daily PEFR variability, salbutamol daily
use, days without use of salbutamol, asthma
attacks, clinical symptoms, symptoms-free days,
morning serum cortisol and vital signs were
analysed by calculating the 95% CI for the mean
change from baseline; an ANCOVA model was used
for between-group comparisons.
Mean values of the run-in period for variables
recorded daily by patients and values measured at
the 2nd clinic visit were the baseline data; 2-
weekly means were also calculated for the daily
recorded variables. Study populations were as
follows: intention-to-treat (ITT), defined as all
randomised patients with post-baseline data; per-
protocol (PP), made of patients in the ITT without
major protocol violations; safety population (SP),
entered by patients having taken at least one dose
of study drug. Missing data were managed using the
last observation carried forward (LOCF) method.
Results
Patients’ disposition and baseline data
Three hundred and thirteen (313) patients in total
were included in the study, 298 (95.2%) of them
were randomised, while 15 (4.8%) were withdrawn
during run-in. Among the 298 randomised patients,
98 (32.9%) patients were assigned to treatment
with HFA twice daily, 103 (34.6%) to CFC and 97
(32.6%) to HFA once daily. Three patients, all in the
CFC group, did not have post-baseline data and
were excluded from ITT population. A total number
of 284 patients (94, 96 and 94 in the three groups,
respectively) completed the 12-week period: the
main reasons of the 14 withdrawals consisted of
adverse events or poor co-operation.
A total of 13 patients had at least one major
protocol violation during the study (poor compli-
ance in eight patients, incorrect use of anti-asthma
medications in four and FEV1 outside the required
range in another) and were therefore excluded
from the PP analysis.
The number of patients taking inhaled corticos-
teroids at study entry and during run-in period was
similar in the three groups: 82 (83.7%) patients in
the HFA twice daily group, 74 (74.0%) in the CFC
group and 78 (80.4%) in the HFA once daily. The
amount of patients taking long-acting b2-agonists
for the total study period was 43.9%, 39.0% and
47.4% in the three groups, respectively, while fewer
patients took xanthine derivatives, leukotriene
antagonists or sodium cromoglycate.
Baseline data (Table 1) were well matched
among the three groups with respect to demo-
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Table 1 Baseline characteristics of the ITT population.
HFA twice daily(n ¼ 98) CFC twice daily(n ¼ 100) HFA once daily(n ¼ 97)
Sex
Males (n) 49 (50.0%) 38 (38.0%) 39 (40.2%)
Females (n) 49 (50.0%) 62 (62.0%) 58 (59.8%)
Age, years (mean7SD) 42.2713.8 43.0714.3 43.8713.9
Height, cm (mean7SD) 169.5710.2 166.778.9 167.4710.3
Weight, kg (mean7SD) 74.0713.6 70.6713.6 75.8712.1
Morning PEFR, l/min (mean7SD) 404.17105.7 386.07104.2 393.8796.5
Evening PEFR, l/min (mean7SD) 412.27106.2 391.97104.8 397.4795.2
FEV1 predicted, % (mean7SD) 77.678.2 77.379.0 77.878.3
N.S between groups for all variables.
Efficacy and safety of inhaled bundesonide S23
graphics, pulmonary function, symptoms, time
from first asthma diagnosis and morning serum
cortisol levels. The mean FEV1% predicted normal
values at study entry were 77.678.2 in the HFA
twice daily, 77.379.0 in the CFC group and
77.878.3 in the HFA once daily group.
Efficacy
Results of the primary variable morning PEFR show
an increase over baseline that was reported from
weeks 1–2 onwards in both the twice daily groups
only (Fig. 1). No statistically significant differences
between groups were reported in the ANCOVA
model in the total population (P ¼ 0:153), as well
as in the steroid-naive subset (P ¼ 0:227). Values of
LSMs were 406.7 l/min in the HFA twice daily group,
402.7 l/min in the CFC group and 396.0 l/min in the
HFA once daily group. The 95% bilateral CI of the
estimate difference between the LSM (4.0 l/min) of
the two twice daily groups in the ANCOVA model
was 6.9 to 14.9, which was well within the710%
of the adjusted mean of budesonide CFC group
(740.27 l/min) thus showing that both the twice
daily groups were equivalent. The comparisons
between both the twice daily regimens with the
HFA once daily also satisfied an hypothesis of
equivalence: 95% CI for the difference between
CFC and HFA (6.7 l/min) once daily was 17.6 to
4.2 and in the comparison of the two HFA regimens
(10.7 l/min) was 0.3 to 21.7.
The analysis of equivalence in the PP population
was consistent with that obtained in the ITT
analysis: the 95% CI for the difference between
HFA twice daily and CFC (4.7 l/min) was 6.4
to 15.9 (limits: 740.10 l/min), values for the
difference between CFC and HFA once daily
(5.7 l/min) were 16.8 to 5.5 and that in the
comparison between the two HFA groups (10.4 l/
min) were 0.8 to 21.5 (limits: 739.54 l/min).
Results of evening PEFR (Fig. 2) were similar to
that obtained in the morning: the 95% CI for the
difference between the LSMs of HFA twice daily and
CFC (2.1 l/min) was 9.4 to 13.5, within the 710%
of value of CFC group (740.87 l/min), that be-
tween LSMs of HFA once daily and CFC (6.8 l/min)
was 18.3 to 4.7, and that between the two HFA
regimens (8.9 l/min) was 2.7 to 20.4 (adjusted
mean of HFA once daily group, 740.19 l/min).
With regards to FEV1 (Table 2), a statistically
significant increase over baseline was reported
from week 2 onwards in each treatment group,
without significant differences between them in
the total population (P ¼ 0:615), as well as in the
steroid-naive subgroup (P ¼ 0:374).
Values of LSMs were 2.66 l in both the twice daily
groups and 2.62 in the HFA once daily group; the
95% CI for the differences was 0.11 to 0.10 in the
comparison between the twice daily groups, 0.15
to 0.06 between CFC and HFA once daily and 0.06
to 0.15 between the two HFA groups, thus showing
an evident proof of equivalence between the three
groups. Results of evening PEFR and FEV1 obtained
in the PP analysis were similar to those of ITT
population (data not shown).
Results of the other PF tests (FVC, PEFR and
MEF50) measured at clinic visits are shown in Table
2: improvements were evident in all the three
treatment groups, but significant increases over
baseline at end-point were obtained in all variables
in both the twice daily groups, whereas the HFA
once daily regimen produced significant increases
only for FVC (Table 2). However, no statistically
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Figure 1 Morning PEFR (l/min) expressed as two weekly
means.
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Figure 2 Evening PEFR (l/min) expressed as two weekly
means.
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significant differences between groups were re-
ported in the ANCOVA model (P ¼ 0:879 for FVC,
P ¼ 0:153 for PEFR and P ¼ 0:211 for MEF50).
Table 3 shows the results obtained in the daily
measurements of symptoms and intake of rescue
salbutamol.
A progressive and statistically significant im-
provement over time of symptoms’ scores and
percentage of symptom-free days was similarly
observed in the three groups (N.S. between groups
for both variables). A statistically significant de-
crease over baseline in the use of rescue salbuta-
mol was also observed at any time point in the two
twice daily groups and from weeks 3–4 onwards in
the HFA once daily group (P ¼ 0:707 between
groups).
Safety
Small and non-significant declines were observed in
mean values of morning serum cortisol in all the
three treatment groups: in the HFA twice daily
group mean baseline values were 399.07
277.6 nmol/l and mean values at week 12 were
382.07166.0 nmol/l; in the CFC group baseline
and final means were 394.37137.6 nmol/l and
377.97158.2 nmol/l, respectively; corresponding
values in the HFA once daily group were
363.57155.5 nmol/l and 354.57161.0 nmol/l, re-
spectively. The comparison between groups of
change from baseline did not show statistically
significant differences (P ¼ 0:960). Individual data
are as follows: nine patients in the HFA twice daily
group, 15 in the CFC group and 18 in the HFA once
daily group had baseline values within the normal
range which declined below the lower limit at the
end of treatment. Conversely, the amount of
patients with low baseline values which entered
the normal range at week 12 was 15, 6 and 13 in the
three groups, respectively.
A total number of 63 adverse drug reactions
(defined as those adverse events with definite,
probable, possible or doubtful relationship to study
medication), with 15 (in 11 patients, 11.2%) in the
HFA twice daily, 20 (in 11 patients, 10.8%) reported
in the CFC group and 28 (in 20 patients, 20.6%)
reported in the HFA once daily group. The
comparison between groups of the distribution of
drug-related adverse events did not show statisti-
cally significant differences between groups
(P ¼ 0:113). Most of these events consisted of local
effects (i.e. cough, dysphonia, pharyngo-laryngitis,
rhinitis and oral mycosis), which occurred in eight
patients in the HFA twice daily group, in seven in
the CFC group and in 12 in the HFA once daily
group. In addition, a taste dislike was reported by
three (3.1%), five (4.9%) and eight (8.2%) patients in
the three groups, respectively, as a probable result
of HFA-134a intake (with active or placebo)
propellant. Only two patients reported serious
adverse events (hospitalisation), both of which
were not related with study drug.
No clinically significant changes over baseline
were observed in vital signs (pulse rate and blood
pressure). An excellent proof of compliance was
observed in the three groups: the mean percen-
tages (7SD) of administered drug in respect of that
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Table 2 Pulmonary function tests during the study (ITT population).
Group Baseline
(mean7SD)
Week 2
(mean7SD)
Week 4
(mean7SD)
Week 8
(mean7SD)
Week 12
(mean7SD)
FEV1 (l) HFA twice daily 2.6370.67 2.7070.78
n 2.7470.78n 2.7470.82n 2.7770.80n
CFC twice daily 2.4670.69 2.5370.81n 2.6170.79n 2.6370.85n 2.6370.83n
HFA once daily 2.4470.68 2.5670.76n 2.5370.78n 2.5470.79n 2.5470.77n
FVC (l) HFA twice daily 3.5470.97 3.5971.08 3.6371.05n 3.6271.04n 3.6571.05n
CFC twice daily 3.2870.91 3.3570.96n 3.4070.93n 3.4471.00n 3.4670.97n
HFA once daily 3.2670.97 3.3871.00n 3.3370.99 3.3670.99n 3.3971.00n
PEFR (l/min) HFA twice daily 364.67111.5 388.07121.4n 381.27117.5n 388.97125.5n 397.57133.1n
CFC twice daily 336.87110.7 358.67114.6n 369.37114.3n 374.97124.9n 370.67118.3n
HFA once daily 352.67110.6 376.07124.2n 367.17122.0 364.97115.9 364.27120.9
MEF50 (l/s) HFA twice daily 2.7071.06 2.8371.21 2.9071.18
n 2.8771.25n 2.9171.24n
CFC twice daily 2.5371.16 2.7371.37n 2.8171.34n 2.8371.40n 2.7871.35n
HFA once daily 2.5571.12 2.6771.12 2.6971.21 2.6571.25 2.6071.21
nPo0.05 vs. baseline.
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scheduled on the basis of the extent of exposure
were 97.479.3 in the HFA twice daily group,
97.675.8 in the CFC and 97.975.1 in the HFA
once daily group.
Discussion
The results of the present study have demonstrated
an exact proof of clinical and statistical equiva-
lence in the comparison of budesonide HFA and CFC
given in the twice daily regimen both in the
pulmonary function and in the symptoms scoring,
thus showing that the administration of inhaled
budesonide with the HFA-134a propellant does not
modify the efficacy in respect with a similar
budesonide CFC dosing. The primary outcome
variable morning PEFR showed significant improve-
ments in both the twice daily groups, with mean
increases in the final period of 11.4 l/min in the
budesonide HFA group and of 9.5 l/min in the
budesonide CFC group, being the 95% CI for the
differences between groups (6.9 to 14.9) com-
prised in a very narrow range, well within the pre-
defined limit of 10% of the reference LSM.
Improvements observed in the HFA once daily group
(1.8 l/min in the final period), despite satisfying the
pre-defined limit for equivalence, were not sig-
nificant and were lower to that obtained in the
other groups.
The results obtained in evening PEFR, as well as
for PEFR or MEF50 measured at clinic visits, were
consistent with those of the primary variable, as
both the twice daily regimens produced more
relevant increases than the once daily group,
although differences in the two-by-two compar-
isons were not significant. The results of FEV1 (and
that of FVC) showed statistically significant im-
provements over baseline in all the three groups at
all visits and FEV1 final values increased of 0.14 l in
the two twice daily groups, and of 0.09 l in the HFA
once daily group. The analysis of equivalence
showed that the 95% CIs were comprised in a very
narrow interval in the comparison between the two
twice daily groups (0.11 to 0.10 l) and well within
the pre-defined limit in the comparisons with the
once daily dosing. Also, the results of symptoms
and use of rescue salbutamol showed an overall and
significant similar improvement in the three
groups, without significant differences between
them in any of the considered variables.
Importantly, the three groups were well matched
for asthma severity and baseline values of all
efficacy and safety parameters; the overall FEV1%
predicted at study entry was 77.6, with similar
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values in the three groups, thereby showing a
satisfactory room for improvement and a potential
sensitivity to detect differences between them. To
establish true clinical equivalence, it is essential
that the compared drugs show a real improvement
from baseline to end-point14; the small improve-
ments obtained in the once daily group in the
primary and in some of the secondary efficacy
variables, compared with both the twice daily
groups, confirm that this study met this require-
ment. However, it should be also noted that,
according with actual trend in prescription and
with international guidelines,15 an overall propor-
tion of patients in this trial (more than 40%) were
using long-acting beta2-agonists at study entry and
this treatment could not have been discontinued
during the treatment phase. This proportion is
higher than that reported in similar studies
previously done,5,6 and this evidence could explain
the moderate improvements in lung function
obtained in the two twice daily groups.
Minimal and similar decreases of mean values of
morning serum cortisol (17 nmol/l in the HFA
twice daily group, 16.4 nmol/l in the CFC group
and 9.0 nmol/l in the HFA once daily group) were
reported in the three groups, without statistically
significant differences between them. The analysis
of patients whose baseline level decreased below
the lower limit of normal range and whose low
baseline was restored at the end of treatment gave
better results in the HFA twice daily group (nine
and 15 patients, respectively), compared with the
CFC (15 and six) and the HFA once daily group (18
and 13). Considering that a proportion of approxi-
mately 20% of patients were not treated with
inhaled corticosteroids at study entry and during
run-in, and that in any case the dose of previous
inhaled corticosteroids was not decreased with the
study treatment, the individual values show a lack
of any detrimental effect of budesonide given
twice daily via the HFA-134a, in terms of possible
adrenal suppression.
The proportion of patients who experienced
adverse drug reactions was low in both the twice
daily groups, accounting for 11 patients (11.2%) in
the HFA and 11 (10.8%) in the CFC group, whereas
the frequency of adverse drug reactions was almost
doubled in the HFA once daily group, as they
occurred in 20 patients (20.6%) and mainly con-
sisted of typical local effects of inhaled glucocorti-
costeroids. Among the reported adverse drug
reactions, a sensation of unpleasant taste, which
is a well recognised effect when a HFA-containing
inhaled drug is started16,17 and generally requires
an initial adaptation, was described by three
patients in the HFA twice daily, five in the CFC
(probably due to the alternative HFA placebo) and
eight in the HFA once daily group. The results
obtained in the once daily group, either obtained in
the general safety profile or relative to taste
dislike, might be due to a double number of puffs
of active drug given simultaneously.
A variety of studies has shown that inhaled
budesonide given once daily is as effective as the
same amount of drug given in divided doses.
However, most of these studies were done with
budesonide pMDI delivered in patients already
receiving inhaled corticosteroids18 or using the
conventional dry powder inhaler (i.e. the Turbuha-
lers) in stable19 or mild asthmatics;20 in addition,
results obtained in relatively short terms were not
confirmed in another study of a 12-month dura-
tion.21 The results of the present study have
indicated that the presumed equivalence between
different dose regimens of inhaled glucocorticos-
teroids is to be interpreted with caution. When
given in patients with a satisfactory room for
improvement, budesonide given once daily with
the HFA propellant produced an overall improve-
ment and a favourable risk-benefit ratio, which was
however slightly inferior compared to the standard
twice daily regimen; it remains a convenient
therapeutical option in patients with mild asthma
or sub-optimal compliance.
We can therefore conclude that the results of the
present study have provided evidence of equivalent
efficacy of inhaled budesonide given with the HFA-
134a or the conventional CFC propellants, when
given twice daily at a microgram-equivalent dose.
The administration of budesonide via the HFA
propellant is also at least as safe as the marketed
CFC-containing product.
List of participating investigators and
study centres
The study was conducted throughout the following
investigators and centres:
Hungary: Vastagh E. (study Co-ordinator), ‘‘Sote
Tudogygogyaszati Klinica’’, Budapest; Devai A.,
‘‘Favarosi Onkormanyzat, Uzsoki Korhaz Tudoosz-
taly’’, Budapest; Herjavecz I., ‘‘Orszagos Koranyi
TBC Intezet Pulmonologia’’, Budapest; Lukacs J.,
‘‘Szent-Janos Korhaz Tudoosztaly’’, Budapest;
Petho L., ‘‘Budai MAV Korhaz I. Pulmonologia’’,
Budapest; Poland: Adamek-Guzik T.; ‘‘Poradnia
Alergologiczna, Szpital Specjalistyczny’’, Krakow;
Kuna P., ‘‘Klinika Pulmonologii i Alergologii’’, Lodz;
Skucha W., ‘‘SPZOZ w Proszowicach Oddzial
Chor!ob Pluc i Gruzlicy’’, Proszowice; Nalepa P.,
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‘‘V Wojskowy Szpital Kliniczny Samodzielny Pub-
liczny Zaklad Opieki Zdrowotnej Oddzial ch. Pluc’’,
Krakow; Szafranski W., ‘‘Oddzial Pulmonologiczny
Wojew!odzki Szpital Specjalistyczny’’, Radom;
Romania: Bogdan M.A., ‘‘Institutul National de
Pneumologie Marius Nasta’’, Bucharest; Calistru
P., ‘‘Spitalul Clinic Victor Babes’’, Bucharest; Isac-
off D., ‘‘Spitalul Clinic Coltea’’, Bucharest; Poposcu
E., ‘‘Saint Maria Hospital’’, Bucharest; Radu J.R.,
‘‘Spitalul Clinic Nicolae Malaxa’’, Bucharest;
France: Courtois L., Rueil Malmaison; Delsaux
M.C., Gournay sur Marne; Douillet C., Monterau;
Martinat Y., ‘‘Centre M !edical Parot’’, Lyon; Ortolan
D., Villejuif; Pigearias B., Nice; Schwender D.,
Dijon.
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